Windtree Therapeutics, Inc. Revenue Growth

Revenue Growth of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Revenue Growth growth rates and interactive chart. Year over year growth in total sales.


Highlights and Quick Summary

  • Revenue Growth for the quarter ending December 30, 2019 was -1.0 (a 17.69% increase compared to previous quarter)
  • Year-over-year quarterly Revenue Growth decreased by -150.49%
  • Annual Revenue Growth for 2019 was -0.89 (a -535.93% decrease from previous year)
  • Annual Revenue Growth for 2018 was 0.2 (a -174.78% decrease from previous year)
  • Annual Revenue Growth for 2017 was -0.27 (a -125.52% decrease from previous year)
  • Twelve month Revenue Growth ending December 30, 2019 was -0.68 (a 46.05% increase compared to previous quarter)
  • Twelve month trailing Revenue Growth decreased by -435.05% year-over-year
Trailing Revenue Growth for the last four month:
30 Dec '19 29 Jun '19 30 Mar '19 30 Dec '18
-0.68 -0.47 0.1 0.2
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Revenue Growth of Windtree Therapeutics, Inc.

Most recent Revenue Growthof WINT including historical data for past 10 years.

Interactive Chart of Revenue Growth of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Revenue Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -1.0 -0.85 -0.8 -0.89
2018 1.98 12.47 -0.08 -0.07 0.2
2017 -0.89 -0.98 9.82 1.92 -0.27
2016 0.37 13.56 0.41 -0.61 1.07
2015 -0.45 -0.87 -0.93 5.16 -0.65
2014 15.0 7.78 5.01 -0.57 6.31
2013 -0.63 -0.84 0.99
2012 -0.66

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.